Vijayshree Yadav, MD
Neurology · Portland, ORNPI 1043225550
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,570 of the $19,944 with a category attached, or 93.1%. EMD Serono, Inc. accounts for 68.7% of it on its own, with 3 other manufacturers making up the rest. 2023 is the largest year on record at $10,247, 2.1 times the $4,785 reported in 2019. Among neurology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $1107.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$14K
- AstraZeneca$5K
- Janssen Scientific Affairs, LLC$1K
- Biogen$132
Across 2 payments — averaging $24,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$49K
What the payments were for
- Consulting fees$18,57093%
- Travel & lodging$9135%
- Food & beverage$3292%
- Education$1321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 9 | $13,707 |
| AstraZeneca | 6 | $4,785 |
| Janssen Scientific Affairs, LLC | 1 | $1,320 |
| Biogen | 2 | $132 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evobrutinib$9,730
- Mavenclad$3,520
How this compares
$19,944 in reported general payments places this provider in the 90th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 27 | $231,268 |
| Kesimpta PenOfatumumab | 18 | $179,781 |
| Plegridy PenPeginterferon Beta-1a | 21 | $167,034 |
| BetaseronInterferon Beta-1b | 17 | $159,488 |
| CopaxoneGlatiramer Acetate | 18 | $103,585 |
| Glatiramer Acetate | 22 | $42,408 |
| Dimethyl Fumarate | 38 | $36,948 |
| Dalfampridine ErDalfampridine | 25 | $19,208 |
| CellceptMycophenolate Mofetil | 13 | $13,432 |
| Modafinil | 16 | $3,570 |
| Baclofen | 103 | $2,337 |
| Gabapentin | 37 | $1,376 |
| Methylphenidate Hcl | 27 | $1,348 |
| Mycophenolate Mofetil | 13 | $708 |
| Lamotrigine | 19 | $369 |
Paid to pharmacies, not to this prescriber.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Nizar ChahinPortland$57K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.